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A B S T R A C T
Medicines are meant to help people and treat their conditions and to promote general well-being of all members
of the society. Unfortunately, this is being compromised by the distribution and sale of poor-quality medicines
around the world, being a consequence of non-GMP manufacturing. In this study, the contamination of the outer
primary packaging with active pharmaceutical ingredient (API, i.e. artemether) is investigated as a possible and
objective, quantifiable marker for GMP-compliance. First, an analytical UPLC-MS method was developed and
verified for artemether, with emphasis on the quantification in the lower concentration range. Second, a
swabbing procedure for the outer surface of plastic bottles (powders for suspension) was developed, including a
swabbing recovery of the API from the bottle surfaces. Finally, twenty antimalarial samples were investigated.
All of them showed some degree of outer contamination; however, large differences in the amount of API
contamination between the different samples was observed, ranging between 4 and 144 ng/cm2. A positive
correlation was found between the amount of artemether on the packaging and the number of information
elements missing on the packaging or leaflet, which was used as one of the tools to evaluate the GMP status of
the manufacturer.
1. Introduction
Good Manufacturing Practices (GMP) in the pharmaceutical in-
dustry is the whole of all requirements that need to be met to ensure
that products are produced and controlled in conformance with quality
standards. Adherence to the GMP regulations thus provides medicinal
products which consistently reach key quality attributes (e.g. identity,
strength, quality and purity of drug products) and guarantees the safety
and efficacy of the products [1,2].
The lack of a robust medicines quality assurance system and poor
compliance with GMP standards can lead to poor-quality medicines.
Poor-quality medicines thereby increase risks of morbidity and mor-
tality due to an increased risk of treatment failure (including resistance
development), adverse drug reactions (due to e.g. chemical, physical
and biological impurities) or prolonged illness. Complications could
thus arise and additional treatments would be necessary. Moreover,
besides the risks on health outcomes, these poor-quality medicines also
increase costs for patients and the health system, as well as deteriorate
the public perception of healthcare [3].
Poor-quality medicines is a more general term for all medicines that
are of insufficient quality. It includes the substandard medicines, which
are defined as “authorized medical products that fail to meet either
their quality standards or specifications, or both”. Substandard medi-
cines can result from human error or negligence at manufacturing sites,
resulting in e.g. a too high level of impurities but also from degradation
of the active pharmaceutical ingredient (API) due to bad storage or
transport conditions. Corrective actions for these substandard medi-
cines therefor include the strengthening of the regulatory quality with
the manufacturer as well as the capacities of National Regulatory
Authorities for compliance audits and enforcements [4].
In their meta-analysis, Ozawa et al. estimated the prevalence of
poor-quality medicines in low- and middle-income countries to be as
high as 13.6%, with a regional prevalence of 18.7% in Africa and 13.7%
in Asia [3]. Also the World Health Organisation (WHO) is aware of this
problem: in their research, it was indicated that 1 in 10 medical pro-
ducts circulating in those countries is substandard or falsified [5]. Due
to the poor pharmaceutical governance, weak technical capacity and
poor supply-chain management, this problem is higher in low- and
middle-income countries, compared to the Western market [6].
Good Manufacturing Practices (GMP) is thus key in the manu-
facturing chain of high-quality medicines, but only works when it is
implemented consistently and rigorously. Regular evaluation of the
quality system is necessary, and can be performed by remote assess-
ment or on-site visits (inspections, audits). The inspection findings of
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the European Medicines Agency (EMA) are currently structured using
approximately 40 categories of deficiencies, of which category 9 is
evaluating the chemical contamination; deficiencies are thereby clas-
sified as ‘critical’, ‘major’ or ‘significant’ [7]. However, ideally, the GMP
status of the manufacturer should be assessed in an objective and
quantitative way. We introduce here the concept of a ‘GMP-marker’,
which can be used (1) by the competent authorities to evaluate the GMP
status of manufacturers, especially in low- and middle income coun-
tries, seen the high prevalence of poor-quality medicines and the lack of
stringent GMP-audits in these countries, (2) by the manufacturer itself
to perform internal verifications of the working procedures, including
trend analyses, or (3) by a contract giver to supplement the ‘at distance’
inspections currently performed. This marker should not replace the
current GMP evaluation procedures, but can rather be used as an ad-
ditional evaluation tool. In this study, the contamination of the primary
packaging of medicines is evaluated to be used as such a GMP-marker.
Medicines at a high-risk of low quality were chosen for this
investigation.
2. Materials and methods
2.1. Chemicals and reagents
UPLC grade methanol, ammonium acetate and glacial acetic acid
were obtained from Biosolve (Valkenswaard, The Netherlands) and
ultrapure water of 18.2MΩ× cm quality was produced by an Arium
pro VF TOC water purification system (Sartorius, Göttingen, Germany).
HPLC grade acetone was supplied by Fisher Scientific (Hampton, NH,
USA). Artemether secondary standard was obtained from Dafra Pharma
(Turnhout, Belgium).
2.2. Identification of medicines at risk
To find out which medicines are most frequently found to be
substandard, different databases worldwide were consulted. From
the U.S., the Medicines Quality Database (MQDB), Food and Drug
Administration (FDA) warning letters and inspection database and FDA
recalls were investigated. The search terms used in the MQDB were: all
available geographical locations (i.e. Africa, Asia and South America)
from 2012 to 2017, all therapeutic indications, all facility info and with
“fail” as final test result from both compendial and screening tests.
Optional fields were then selected to obtain more information: name of
manufacturer, Active Pharmaceutical Ingredient(s) (API), dosage form,
the type and sector of facility (i.e. in what kind of facility the sample
was obtained and whether it was a public or private facility) and the
date the sample was collected [8,9]. For the FDA warning letters da-
tabase and the FDA inspection database for Drug Quality Assurance,
information from 2016 to 2018 (last consulted: February 2018) was
examined for manufacturers answering inadequately to GMP; for the
FDA list of medicines that had been recalled, issues between 2014 and
2018 (last consulted: February 2018) were examined.
The European Medicines Agency (EMA) withdrawals and the
European GMP-compliance database, i.e. EudraGMP, were consulted as
the European sources. From the EMA list of withdrawals, a ranking was
made to evaluate which medicines were most frequently recalled.
The information from the World Health Organisation (WHO) was
also accessed through the Global Surveillance & Monitoring System
(GSMS) for substandard and falsified medical products and the
Medicine alerts (between 2013 and 2018). Based on the available data,
a list of the most frequent substandard or falsified medicines was made.
Finally, also the scientific literature databases Web of Science and
PubMed were consulted to observe which medicines were found to be
most frequently substandard. Search terms were “falsified OR coun-
terfeit OR substandard AND medicines” in the topic and “prevalence OR
frequency” in the title. Both falsified and substandard medicines were
included in the literature search to detect all described poor-quality
medicines.
2.3. Samples
The artemisinin-based combination therapy (ACT) medicines used
in this study all contained artemether and lumefantrine in a dose of
3mg/ml and 18mg/ml, respectively. These samples, i.e. powders for
oral suspension for paediatric use, were covertly purchased in Kinshasa,
the capital of the Democratic Republic of Congo (DRC), from licensed
wholesalers. Samples were packed in zip-lock plastic bags upon col-
lection and transferred in cardboard boxes from Kinshasa to Belgium.
The samples were stored and transported under controlled conditions,
defined by WHO, i.e. max. 30°C and 65% relative humidity [10].
2.4. UHPLC-MS method
Chromatography was performed using a Waters Acquity UPLC,
consisting of an Acquity sample manager, an Acquity quaternary sol-
vent manager, an Acquity UPLC High Temperature Column Heater and
an Acquity Single Quadrupole QDa MS-detector module, operated using
the Empower 3 Chromatography software. An Acquity UPLC BEH
Shield RP18 column (100mm×2.1mm, 1.7 μm), held at 40°C
(± 5°C), was used for the analyses (all from Waters, Zellik, Belgium).
A gradient was used with two mobile phases: (A) a methanol/
10mM ammonium acetate (10/90 v/v) mixture with 0.1% glacial
acetic acid, and (B) a methanol/10mM ammonium acetate (95/5 v/v)
mixture with 0.1% glacial acetic acid. A 3min isocratic period with
85% of mobile phase A was initiated, followed by a second linear period
of 2.9 min with 6% of mobile phase A; after a 1min gradient time to
100% of mobile phase B, returning to the starting conditions was
achieved, resulting in a total run time of 10min. The flow rate was set
at 0.4 ml/min, with an injection volume of 5.0 μl.
Detection and quantification was performed with a Single
Quadrupole QDa MS-detector. As the most abundant ion for artemether
was found to have a m/z value of 221 (detection window: 5–10min,
with artemether eluting around 6min), this ion was used in SIR mode
for the quantification of the API; the cone voltage was set at 15 V, the
capillary temperature at 400 °C and the capillary voltage at 0.8 kV.
Nitrogen nebulizing gas was supplied at a pressure above 600 kPa.
Quinine contamination was investigated as well, seen their similar
therapeutic classes and thus possible cross-contamination during man-
ufacturing; a m/z of 325 (SIR mode) was therefore investigated during
the first 5min of the analytical method.
2.5. Swabbing method
Special attention was given to the handling of the samples: (1) they
were only handled when wearing nitrile gloves, (2) the bottles were
only removed from their secondary packaging right before the analysis,
and (3) analysts could only touch the lid of the bottle, without touching
the rest of the bottle to avoid contamination with or elimination of the
residues.
An area of 25 cm2 was marked on each sample bottle using a paper
pattern (5 cm×5 cm), with each area containing both plastic and label
material (randomly chosen) (Fig. 1). A small ball of cotton wool (VWR,
Radnor, PA, USA), with an approximate weight of 50mg, was then
wetted with methanol and handed with a stainless steel forceps during
the swabbing of the area. Swabbing was performed in two directions in
a standard way, i.e. first vertically, then horizontally and finally again
vertically. Swabbing was performed in triplicate, each with a different
ball of cotton wool. Each swab was then transferred to a 150ml Er-
lenmeyer flask, after which 10.0ml methanol was added and the so-
lution shaken for 30min with a mechanical shaker (CAT Ingenieurbüro,
Staufen, Germany). After 30min, the swabs were removed using a
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spatula and by squeezing all liquid left in the cotton wool ball into the
Erlenmeyer flask. The solvent was then evaporated until dryness using
nitrogen gas, followed by a reconstitution of the residue in 3ml of
methanol. 500 μl was then centrifuged using an Eppendorf 5471 R
centrifuge (Eppendorf, Hamburg, Germany) at 20000 rpm for 5min at
room temperature. Finally, the supernatant was analysed using UPLC-
MS. A scheme of this swabbing procedure is given in Supplementary
Information 1.
After the swabbing of the samples, for each sample, the 25 cm2
swabbing area was spiked with 3 μl of a 350 μg/ml artemether solution
in acetone to evaluate the recovery of the swabbing procedure. The
spiked surface was then swabbed in the same way as described for the
samples.
Quantification of artemether in the swabs was based on the peak
area of artemether, corrected for the peak area in the blank samples.
Peaks were integrated in baseline-to-baseline mode, using the Empower
3 software. The corrected peak area of each swab solution was then
used to calculate the amount of artemether extracted from the surface,
expressed as ng/cm2; calculation is thereby based on a one-point cali-
bration using the 350 μg/ml artemether reference solution (i.e. 42 ng/
cm2). However, the recovery of artemether from the bottle surface
should be included as well; as different manufacturers have different
bottles and labels, and hence as well chemical as physical properties,
different recoveries are expected. Recoveries for each bottle are thus
calculated from the artemether amounts in the swabs from the spiked
samples after the triple-swabbing for assaying.
2.6. Method verification
Currently, there are no formal guidelines for the validation of
methods for this purpose. Therefore, we performed a method verifica-
tion based on the recent guideline for bioanalytical method validation
of the FDA. As stated there, analytical methods should only undergo
full, formal method validation when they are used to make regulatory
decisions. Methods that are not meant for regulatory decision-making,
should be fit-for-purpose [11]. Therefore, this developed method is only
subjected to a verification and not to a full, formal validation; linearity,
recovery, stability, accuracy and precision were verified for this study.
3. Results and discussion
3.1. Identification of medicines at risk
From the MQDB, 145 poor-quality medicine samples were found in
total. From these, 29 samples contained the artemether/lumefantrine
API combination, which is used as an anti-malarial product. Next, 15
samples were found to contain either quinine or the artesunate/amo-
diaquine combination product, both again used in the treatment of
malaria. Medicines that were affected by a recall between 2014 and
2018 were almost exclusively parenteral solutions (83.1%), ranging
from saline solutions and eye irrigation fluid to antineoplastic drugs
and other medicines known to be administered parenterally; the main
quality issues were therefore sterility problems (30.3%) and the pre-
sence of particles (44.9%).
The information from the European databases indicated that the
main reason for withdrawal of medicines was the unsatisfactory
quantitative and qualitative composition of the medicines. These pro-
ducts included, but were not limited to, centrally authorized products.
Unlike the list of FDA recalls, withdrawn products on the EMA list are
not limited to parenteral medicinal products. Moreover, the EU with-
drawals concerned products that are commonly produced, marketed
and used in Europe, meaning that products like anti-malarial and anti-
tuberculosis medicines are not mentioned in the list. Another ob-
servation was that all withdrawn medicinal products that contained the
same API came from the same manufacturer. Comparing the manu-
facturers whose products were withdrawn from the market with the
manufacturers mentioned in the GMP non-compliance reports in the
EudraGMP database, indicated no match, meaning that the withdrawals
were not caused by GMP non-compliance.
The WHO GSMS reported different substandard and/or falsified
medicines, which can be divided into different therapeutic classes; the
anti-malaria, antibiotics and anaesthetics/painkillers were found to be
the most frequently reported therapeutic classes of medicines that are
substandard and/or falsified. Next, the alerts between 2013 and 2018
(n= 21) reveal only one incident with a non-falsified product. The
incident involved dextromethorphan syrup which was contaminated
with the potent related substance levomethorphan. All other alerts
(n= 20) were falsified products, containing no or virtually no API.
Using the systematic search in Web of Science and PubMed, 52 hits
were obtained. Most of these publications were not directly related to
medicines (n=34) or poor-quality medicines (n=6), and for two
publications, the full text was not available. From the remaining pub-
lications (n= 10), nine were focussing on the prevalence in a specific
area or country, while one was a systematic review of all publications
on poor-quality medicines from 2007 to 2016. From the 41 included
studies described in the review, anti-malarial products had showed
failure rates of 0–80%, while for antibiotics, the failure rate was 0–27%.
Other classes like anthelmintics, uterotonics, growth factors and proton
pump inhibitors have also been studied, but less frequently and with
less samples. Other publications concern separate studies about quality
issues with i. a. anti-tuberculosis medicines [12], medicines for ma-
ternal care [13] and peptide medicines [14].
So, the therapeutic class that came out most frequently as sub-
standard medicines were the anti-malarial drugs. Therefore, our re-
search was further focussed on the packaging analysis of artemether/
lumefantrine combination products as a frequently used anti-malarial
representative.
4. Method development
The development of the analytical method was based on a pre-
viously developed UPLC-UV method, used for the investigation of β-
artemether degradation, and the described fragmentation patterns
[15,16]. The in-source fragmentation of artemether to a fragment with
m/z 221 was previously described by Vandercruyssen K. et al. [16]. An
Fig. 1. Swabbing of bottles using a paper pattern (5 cm×5 cm).
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ammonium acetate buffer with methanol containing 0.1% (v/v) acetic
acid was used for the UPLC-MS method development. Using the de-
scribed gradient method, quinine eluted after 4.7min and artemether
after 5.4 min.
Both DMSO and isopropanol (1%) were evaluated as possible mo-
bile phase modifiers to increase the MS signal intensity [17]. However,
as no increase in the signal was observed, both additives were not
further used. Changing the cone voltage from 15 V to 10 V or 20 V,
yielded no increase in the mass signal for artemether. Changing the
capillary temperature from 400°C to 300°C or 500°C led to inconsistent
fragmentation of artemether and decreased signal intensities; hence,
the capillary temperature was kept at 400°C.
5. Method verification
Linearity of the UPLC-MS method was verified using four arte-
mether reference solutions (i.e. 100 ng/ml, 160 ng/ml, 260 ng/ml and
500 ng/ml): the calibration curve was found to be linear with an R2 of
0.995; the confidence interval on the y-intercept also included zero.
The recovery obtained with the swabbing protocol was assessed
using four concentration levels of artemether, i.e. 100 μg/ml (12 ng/
cm2), 160 μg/ml (19.2 ng/cm2), 260 μg/ml (31.2 ng/cm2) and 600 μg/
ml (72 ng/cm2). Pre- and post-spiked swabs were compared, resulting
in a recovery of around 56%, based on the slopes of both calibration
curves.
The linearity of the swabbing method was estimated based on the
calibration curve of the pre-spiked samples: a R2 of 0.9191 was found,
with a significant deviation from the curve for the points in the lower
concentration range.
The accuracy and precision of the swabbing method was estimated
using quality control (QC) samples of 133 μg/ml (16 ng/cm2) and
500 μg/ml artemether (60 ng/cm2), both prepared in duplicate. The
accuracy was found to be 108.9% and 103.8%, respectively; the coef-
ficient of variance for the QC standards was 9.4% and 7.7%; respec-
tively.
The analytical stability of an artemether sample (200 μg/ml) was
evaluated at room temperature, as sample preparation and sample
storage during UPLC-MS analysis was performed at this temperature.
The solution was found to be stable for at last 24 h, but after two days, a
significant decrease in signal was observed.
5.1. Quantification of artemether on the primary packaging
The recovery of artemether from the packaging was investigated
using three consecutive, combined swabs from the spiked sample. The
results of this recovery are given in Fig. 2. There is a significant dif-
ference (one-way ANOVA, p= 0.0031) observed between the recovery
with the different brands: the recovery from the Mefanther samples
showed to be statistically significant from the recovery from the Cether-
L, Co-Artesiane and L-Artem samples.
Seen the difference in the recovery of artemether between the dif-
ferent brands/manufacturers and sometimes even between different
bottles from the same brand/manufacturer, the plastic material of the
bottle is likely to affect the recovery of artemether from the surface.
Products of the same batch also do not necessarily have the same re-
covery as different batches of plastic bottles can be used in the same
batch of medicine. Moreover, the 25 cm2 swabbing surface did consist
of plastic material and label material, with different relative propor-
tions plastic/label.
One possible explanation of the recovery differences is the rough-
ness of the used plastic and label: a coarser surface has more crevices in
which particles and solvents can settle, which makes it harder to extract
all artemether from the surface. An illustration can be seen in Fig. 3.
The artemether that is readily available on the surface can be easily
swabbed, but the more deeply situated, artemether is harder and maybe
impossible to extract in this way.
The amount of artemether obtained after three consecutive swab-
bing procedures is given in Fig. 4. In general, the amount of artemether
found in the swabbing samples decreased as the number of swabs in-
creased. Interestingly, after spiking the sample bottles with a known
amount of artemether (3 μl of a 350 μg/ml artemether solution), it was
found that three consecutive swabbings did not give 100% recoveries
(see Fig. 2). Therefore, it was decided to correct the experimentally
found residue on that bottle using the bottle-specific recovery, giving
the final artemether amounts as visualized in Fig. 5.
Every tested anti-malarial powder for suspension sample demon-
strated to have some artemether active pharmaceutical ingredient
present on the primary packaging. The highest level of artemether was
found on a Cether-L sample (i.e. 144 ng/cm2). For Mefanther and Co-
Artesiane, the mean amount of artemether on the bottles was lower
than the mean amount on the Cether-L samples; some samples of both
brands however do show higher levels of artemether than some of the
Cether-L samples. For these three brands, also a higher variability is
observed between the obtained swab results. The variability is much
smaller with the L-Artem samples. These last samples demonstrated to
have low levels (7–12 ng/cm2) of artemether on the primary packaging
as well.
In previous studies examining the surface contamination of the
primary packaging of samples (mostly anti-cancer products), collected
Fig. 2. Recovery of a spiked artemether reference on the primary packaging of
different anti-malarial samples. The dot plot indicates the mean (red line) re-
covery of the different samples from the same brand (n= 5 for Mefanther,
n=4 for Cether-L, n= 3 for Co-Artesiane and L-Artem, n=1 for others). (For
interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
Fig. 3. The roughness of a surface. Plastics/labels are not perfectly smooth and
have some degree of roughness on their surface. This contributes to a decreased
recovery as not all artemether is easily accessible from the surface (Figure
adapted from Ref. [18]).
E. Wynendaele, et al. Talanta 201 (2019) 259–265
262
on western markets to assess the toxicity risk for the hospital staff
handling these products, the amount of API found on the primary
packaging (often glass vials) ranged between no contamination found
and 2.5 ng [19–24], without detailed information on the surface area of
the vials. The highest primary packaging contamination of the in-
vestigated anti-malarial samples in this study, was 3605 ng artemether
(25 cm2 swabbing area). While the surface area of the glass vial is
generally lower than our investigated 25 cm2 surface area, the values
found are still lower than our values, which can be due to higher GMP
levels but also to the glass versus plastic/label surface.
According to reports of the Dutch inspection of public health,
Manufacturing Packaging Farmaca (MPF), which is the manufacturer of
the Co-Artesiane samples, is compliant to GMP [25]. No information
could be found on the GMP compliance of the other manufacturers, i.e.
New Cesamex (Cether-L), Shalina Laboratories (L-Artem), Ave Pharma
(Lufamet), Ally Pharma Options (Mefanther), Bliss GVS Pharma (Gvi-
ther Plus), Zenufa Laboratories (Co-Artluf), Jiangsu Ruinian Qianjin
Pharmaceutical (Arlu) and Zest Pharma (Luther). WHO prequalification
could not be used to identify GMP compliant manufacturers, as pae-
diatric powders for suspension are not yet covered by prequalification.
So, only the samples of Co-Artesiane could be viewed as being produced
in a GMP compliant way. Based on the limited information about GMP
compliance of the manufacturers in this study, no direct relationship
between GMP compliance and the amount of API on the primary
packaging could thus be obtained so far. Therefore, despite the lack of
an unambiguous correlation, the GMP compliance status was assessed
using the information quality on the anti-malarial samples. This cri-
terion evaluates the availability of regulatory information on the pri-
mary and secondary packaging and on the leaflet that is included with
the medicine, based on WHO recommendations (Supplementary In-
formation 2 and 3) [10]. Based on the twenty evaluated anti-malarial
samples, except for the first points, a certain tendency of relationship
was observed between the number of missing information elements and
the surface area contamination of artemether found on the primary
packaging: in general, the higher the number of missing elements, the
higher the surface area concentration of artemether that was found on
the primary packaging (Fig. 6). Although in this study only one aspect
of the multifactorial GMP concept is studied, a certain relationship
between the amount of API on the primary packaging and the GMP
compliance status can not be excluded. The use of the API amount on
the primary packaging as a GMP-marker thus seems useful.
The main focus of this study was investigating the presence of a
certain API that should be present inside the bottle. Future studies
should however also look at other chemical and even biological con-
taminants; if other contaminants are observed on the packaging, it can
be concluded that no clean working environment is present, re-
presenting a poor GMP status of the manufacturer. This marker thereby
also allows a quantitative follow-up of the corrective actions performed
by the manufacturer.
Having a look on the amount of API that was found on the outer
packaging material (i.e. up to 144 ng/cm2), makes it clear that the
contamination itself may not be ignored from a safety perspective as
well, due to resistance considerations. Moreover, this surface con-
tamination is probably not limited to antimalarial medicines alone and
other therapeutic classes may be affected as well. Recent studies show
that sub-minimum inhibitory concentrations (MIC) of antibiotics con-
tribute to the development of antibiotic-resistance [26]. Contamination
Fig. 4. The amount of artemether found in three subsequent
swabs of the primary packaging. When the signal was below
the analytical detection limit (LOD, i.e. 0.104 ng/cm2 for an
individual swab), the value for these swabs in the dot plot is
LOD/2, to still weigh those swabs in the determination of
the mean (red line) (n=5 for Mefanther, n=4 for Cether-
L, n= 3 for Co-Artesiane and L-Artem, n= 1 for others). A
general downward trend in the median amount of arte-
mether can be seen as the number of swabs of the same
surface increases. (For interpretation of the references to
colour in this figure legend, the reader is referred to the Web
version of this article.)
Fig. 5. Surface area concentration of artemether found on the packaging (i.e.
sum of the artemether amount in the three swabbing results), corrected for the
bottle-specific recovery. The dot plot indicates the mean (red line) amount of
artemether on the different samples from the same brand (n= 5 for Mefanther,
n= 4 for Cether-L, n=3 for Co-Artesiane and L-Artem, n= 1 for others). (For
interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
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of the outer surface of medicines can thus have high impact on patients,
healthcare workers as well as the environment, and needs further in-
vestigations.
6. Conclusions
As poor-quality medicines are a global concern that is still not re-
solved, ways to battle and detect these products are necessary. Efficient,
objective and quantitative ways are to be found to detect such medi-
cines, so that distribution of those poor-quality medicines can be pre-
vented, thereby diminishing the health risks for the patients. In this
study, the contamination of the primary packaging of antimalarial
medicines was measured and evaluated to be used as a possible GMP-
marker. All investigated samples (n=20) were found to have some
degree of contamination with artemether, thereby indicating that the
absence of API on the packaging can not be used as an indication of
GMP-compliance. A positive correlation was however observed be-
tween the amount of artemether on the packaging and the number of
information elements missing on the packaging or leaflet, used in this
study as a tool to evaluate the GMP status of the manufacturer.
Moreover, as sometimes quite high amounts of API were found on the
packaging, contamination of the outer surface should not be ignored for
its possible risk of resistance development and possible toxic concerns
in several other therapeutic classes of medicines.
In this manuscript, a new quantitative marker to evaluate the GMP
status of the manufacturers is thus proposed, which can be used as a
non-committal, additional tool in the current GMP evaluation proce-
dures. GMP is an overall multifactorial concept, and this GMP-marker is
a new tool evaluating one of the GMP-factors. Additional data, in-
cluding untargeted and comprehensive contaminant evaluation, should
be obtained to further evaluate the usefulness of this GMP-marker.
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